Coordination of Care/Care Transitions
Nicole Houston, BSN, RN, CCRP, Irene Ekwede, MSN, BSN, RN, Stephanie Morrissey, RN, BSN, Brittany Bowes, RN, BSN, Eleni Rokakis, RN, BSN, Ruth Phillips, RN, BSN, MS, OCN, Ellie Strock, ANP-BC, FAANP, CDE, Christin Whalen, RN, BSN, OCN
Cediranib-olaparib in combination has been shown to cause rapidly escalating hypertension and severe diarrhea in patients treated for ovarian cancer.
The tumor board, or multidisciplinary cancer conference (MCC), is the foundation of high-value multidisciplinary oncology care through coordinating teams of specialists.
The multidisciplinary cancer conference (MCC) plays an integral role in optimizing patient outcomes in today’s increasingly complex world of cancer care.
Accessing chimeric antigen receptor (CAR) T-cell clinical trials for relapsed and refractory B-cell acute lymphoblastic leukemia (ALL) is challenging for pediatric patients who have experienced a relapse of B-cell ALL or have been refractory to standard therapy.
The Johns Hopkins Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Sibley Memorial Hospital, performs more than 500 surgeries annually.
In preparation for the upcoming certification test, information is provided on the essential function of nurse navigations in care coordination to assist navigators.
A review of the literature was done to evaluate the current evidence regarding the barriers that influence the transition of care in cancer survivorship and impact patient quality of life (QOL) and health outcomes.